The PMOS treatment hierarchy

If you have a PCOS diagnosis, what you have is now formally called PMOS (polyendocrine metabolic ovarian syndrome), the new name confirmed by global consensus in May 2026. The diagnostic criteria did not change. The clinical condition did not change. The treatment recommendations did not change. The 2023 International Evidence-based Guideline (Teede et al.), built across 37 experts in 8 countries, endorsed by 39 international organisations, with 254 specific recommendations, remains the global anchor for PMOS management.

Scroll any PMOS forum and a dozen interventions get mentioned in a single thread (supplements, medications, diets, alternative approaches) as if they were all equally evidence-backed. They are not. The Guideline is specific about what goes first, what goes next, and what is adjunctive.

This is an evidence-page article. It is not a recommendation for any individual. Every medication in this article has specific indications, contraindications, and side-effect profiles; the decisions belong with a clinician.

The hierarchy, at a glance

The interventions below are listed in the order the 2023 Guideline supports, with the evidence tier per Cyster’s evidence hierarchy noted.

Tier 1: foundation (recommended for all).

1. Lifestyle foundation. Resistance and aerobic exercise, sleep prioritisation, an overall dietary pattern oriented around protein, fibre, and meal composition rather than restriction, and mental health support. Recommended for all people with PMOS, at all stages, regardless of symptom severity or concurrent treatments. Tier 1: International Guideline first-line.

Tier 1: first-line pharmacological options (by indication).

2. Metformin. First-line pharmacological option for metabolic features (insulin resistance, elevated cardiometabolic risk, type 2 diabetes risk) and frequently for cycle regulation. Used regardless of BMI and regardless of whether prediabetes is present.
3. Combined oral contraceptives (COCs). First-line for cycle regulation, hirsutism, and androgen-driven skin features. Lower-androgenic progestin formulations are preferred.
4. Letrozole. First-line for ovulation induction in PMOS-related infertility. Replaced clomiphene citrate as the international first-line in the 2023 Guideline. The PMOS fertility pillar covers this in depth.

Tier 1: second-line additions and adjuncts.

5. Anti-androgens (spironolactone). Added to COCs when hirsutism or acne do not respond adequately, or as an alternative when COCs are not tolerated. Reliable contraception is required during anti-androgen therapy.
6. Inositol. Listed by the Guideline as an adjunct with limited and inconclusive evidence. Reasonable as a layer for metabolic and ovulatory features, particularly for people who cannot tolerate metformin. Not a substitute for first-line pharmacological options. The evidence summary on inositol covers the fuller picture.

Emerging:

7. GLP-1 receptor agonists. Semaglutide, tirzepatide, and liraglutide. Growing evidence for metabolic, weight, and cycle-regularity outcomes in PMOS. On-label for obesity and type 2 diabetes; off-label for PMOS-specific use. The 2023 Guideline does not endorse this class as standalone PMOS treatment outside of those comorbidity indications. The evidence summary on GLP-1s in PMOS covers this in depth.

Selected cases:

8. Bariatric or metabolic surgery. Considered when lifestyle and pharmacological interventions have not produced adequate outcomes in cases of severe obesity with metabolic complications. Significant PMOS-symptom improvement is documented in most patients post-surgery, alongside the major commitment the procedure represents.

Why "lifestyle first" is genuinely first

The phrase "lifestyle first" can land badly, especially in a clinical history of being told the condition would resolve with trying harder. That is not what the Guideline framing means.

What the evidence supports: specific, measurable interventions (resistance training, an overall dietary pattern oriented around protein and fibre and meal composition, sleep adequacy, mental health support) produce the most durable, side-effect-free improvements across the full spectrum of PMOS outcomes (metabolic, reproductive, and dermatological). Effect sizes are modest individually; they compound; they do not carry medication side effects.

What it does not mean: "lifestyle first" does not mean "lifestyle only." The Guideline is explicit that pharmacological treatment is recommended alongside lifestyle when appropriate, not afterlifestyle has been tried for an extended period and found insufficient. The hierarchy is not "try this for a year, then we will talk." It is "start here, layer on as needed."

First-line does not mean only. It means always: the foundation under everything else added on top.

A note on framing. "Lifestyle" in this article does not include weight-loss-framed plans, calorie morality, or elimination diets. The 2023 Guideline supports a quality-of-pattern approach (protein-and-fibre meal composition, resistance training, sleep) over a restriction-and-weight approach. Interventions that introduce restriction or moralised eating language are out of scope and can deepen patterns that are harder to recover from than the metabolic features they target.

Why metformin before inositol

PMOS community conversations often differ from the Guideline at this point. Inositol has solid evidence; it improves insulin sensitivity and ovulation in a meaningful portion of users. Metformin has more evidence, longer safety data (decades), and typically larger effect sizes in head-to-head comparisons.

Metformin’s cultural framing as "the diabetes drug for overweight patients" is a leftover that the Guideline explicitly pushes against. In PMOS, metformin is used for insulin resistance regardless of BMI, and regardless of whether prediabetes is present. The 2026 Lancet rename consensus reinforces the metabolic centrality of PMOS, with approximately 85 percent of people with PMOS overall, and approximately 75 percent at a lean body weight, showing insulin resistance. Metformin is a PMOS-appropriate medication on its own merits, not a body-size-tagged prescription.

Inositol remains a legitimate option, particularly for people who cannot tolerate metformin, or as an adjunctive layer alongside metformin. It is not Guideline first-line.

Why COCs are both recommended and complicated

Combined oral contraceptives are first-line for cycle regulation and androgen-driven symptoms. They are also a decision many people with PMOS feel ambivalent about. COCs regulate cycles mechanically, by suppressing the body’s own hormone cycle and producing a withdrawal bleed rather than restoring underlying ovulation. They have their own side-effect profile (mood effects, mild venous thromboembolism risk, others). Some people want to preserve underlying fertility pathways rather than mask them.

The Guideline does not resolve this ambivalence. It is explicit that COCs are evidence-based and appropriate for many people with PMOS, and that the decision involves weighing cycle and androgen benefits against other considerations including individual preference. The Guideline’s role is not to prescribe the answer; it is to make clear that COCs are evidence-based, not a fallback.

A note on what COCs do and do not do. They regulate cycles by suppressing ovulation entirely; they do not improve underlying ovulatory function once stopped. They treat androgenic features by lowering free testosterone (in part through SHBG elevation). They do not address insulin resistance directly. For someone whose dominant feature is metabolic, COCs are not the highest-leverage option even when they are appropriate for other reasons.

Why letrozole is first-line for ovulation induction

The fertility-specific first-line changed in the 2023 Guideline. Letrozole, an aromatase inhibitor, replaced clomiphene citrate, which had held the position since the 1960s. The change rests on the 2014 PPCOS II trial (a 750-woman, multicentre, double-blind RCT, published in the New England Journal of Medicine), alongside a sequence of meta-analyses since then. Letrozole produced higher live-birth rates (approximately 27.5 percent versus 19.1 percent across five cycles) with no increase in birth defects.

The mechanism: clomiphene blocks oestrogen receptors throughout the body, including in the endometrium, which thins the lining and degrades cervical mucus. Letrozole lowers oestrogen production briefly during the dosing window and lets the endometrial lining recover. The pregnancy environment is friendlier as a result.

The fertility pillar covers letrozole dosing, monitoring, and the second-line and third-line escalation pathways in depth.

The GLP-1 question

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) have changed PMOS management in real-world clinical practice faster than the Guideline can be updated. Emerging evidence supports substantial weight, metabolic, and cycle-regularity improvements in PMOS users.

What is not settled: long-term safety in reproductive-age women, optimal duration of use, effect on fertility outcomes specifically, what happens after discontinuation, and where these medications fit in the hierarchy relative to metformin for PMOS-specific indications. Many endocrinologists now offer GLP-1 receptor agonists, some as first-line; the Guideline does not formally endorse this. The 2026 Lancet rename consensus notes that several authors declared honoraria from the manufacturers (Novo Nordisk for semaglutide, Eli Lilly for tirzepatide); the consensus itself was not pharma-funded. This is context.

If a GLP-1 receptor agonist is being recommended, reasonable questions to ask:

• Why this medication, before or alongside metformin?
• What is the plan for duration of use?
• What happens if fertility becomes a priority later?
• What is the access and cost picture, and what is the plan if coverage shifts?

The evidence summary on GLP-1s in PMOS covers the full picture, including the pregnancy and contraception considerations.

What is not on the first-line list

Notable absences from the Guideline first-line recommendations, not because they cannot help any individual, but because the evidence does not support them as standard PMOS care:

• Elimination diets (dairy-free, gluten-free, keto, etc.). No specific elimination pattern is evidence-backed as superior across PMOS. A pattern oriented around protein, fibre, and meal composition is supported; specific eliminations generally are not.
• Most single supplements beyond inositol. NAC, berberine, chromium, vitamin D, others. Some have preliminary data; none are Guideline first-line. Inositol is the supplement exception.
• "Seed cycling," "cortisol detoxes," "hormone resets." Not evidence-based; the framing typically misrepresents the underlying biology.
• Compounded hormones outside endocrinologist oversight. Not evidence-based at the over-the-counter or wellness-clinic tier; quality is variable; risks are real.

None of these are banned or automatically harmful for everyone. Some have small evidence bases, individual responses, or particular contexts where they may help. The mismatch worth noticing is spending money and hope on these while deprioritising the Guideline-first interventions that have the strongest evidence.

A useful question for any clinical conversation: "What is the guideline-first approach for my specific situation?" If a clinician does not reference the 2023 International Guideline or a comparable framework, asking what framework the recommendation is based on is reasonable. The conversation tends to clarify whether the recommendation sits inside current evidence or outside it.

A note on individual variation

The Guideline describes what works, on average, for the PMOS population. It does not describe what will work for any individual. Response varies. Side effects differ. Life context matters. Phenotypes vary; the same condition can present quite differently in two people with the same diagnostic criteria met.

The hierarchy is a starting point for an informed conversation, not a ranking of virtue. The best PMOS management is typically layered (foundation interventions plus one or more medications plus adjunctive supports where indicated), individualised (based on the specific phenotype, goals, and life context), and revisited periodically (because PMOS changes across the lifespan).

What the hierarchy does is set the order of conversation. What it does not do is replace the conversation. The 2028 International Guideline update, anticipated in the next two years, will likely refine the GLP-1 framing, the metformin-during-first-trimester question, and possibly the formal recognition of PMOS subtypes. The hierarchy in this article is the May 2026 picture; the next revision will be the next picture.